Endosaccular flow disruption devices

Changed by Henry Knipe, 2 Aug 2020

Back to revision history

Updates to Article Attributes

Title was changed:

~~Flow Disruption Devices~~Endosaccular flow disruption devices

Body was changed:

Show markup changes

Endosaccular flow disruption devices or, also simply known as flow disruptors,are ~~devices~~ used for the treatment of saccular, wide-neck, and usually bifurcation ~~intra-cranial aneurysm~~intracranial aneurysms. Their primary function is to stop blood from flowing into the aneurysm, allowing time for the aneurysm to heal. They are usually tightly packed nitinol-based material in different shapes.

~~There~~Currently (as of 2020) there are four ~~kinds~~types of flow disruptors:

Woven ~~Endovascular Bridge~~EndoBridge (WEB)~~, Luna~~ Aneurysm Embolization System
LUNA™ Aneurysm Embolization System,
Medina Embolic Device (MED)~~, and~~
Contour Neurovascular ~~Devices~~System™

Antiplatelet regimen differs between institutions ranging from mono or dual antiplatelet regimen prior to and after the procedures (depend on concomitant or prior stenting).

Complications

The most common complication is thromboembolism. Delayed ipsilateral parenchymal hemorrhage, a very serious but rare complication, was also reported.

Outcomes

Among them, WEB is the most widely known and studied device. Large European multicenter trials (WEBCAST and WEBCAST 2) illustrated a very high success rate (complete occlusion or neck remnant at one-year follow-up) in 80% with no device-related mortality and only 1.8-2% morbidity.

~~Antiplatelet regimen differs in each center ranging from mono or dual antiplatelet regimen prior to and after the procedures (depend on concomitant or prior stenting).~~

~~The most common complication is thromboembolism. Delayed ipsilateral parenchymal hemorrhage, a very serious but rare complication, was also reported.~~

-Endosaccular flow disruption devices or also known as flow disruptors are devices used for the treatment of saccular, wide-neck, and usually bifurcation intra-cranial aneurysm. Their primary function is to stop blood from flowing into the aneurysm, allowing time for the aneurysm to heal. They are usually tightly packed nitinol-based material in different shapes. There are four kinds of flow disruptors: Woven Endovascular Bridge (WEB), Luna Aneurysm Embolization System, Medina Embolic Device (MED), and Contour Neurovascular Devices. Among them, WEB is the most widely known and studied device. Large European multicenter trials (WEBCAST and WEBCAST 2) illustrated a very high success rate (complete occlusion or neck remnant at one-year follow-up) in 80% with no device-related mortality and only 1.8-2% morbidity. Antiplatelet regimen differs in each center ranging from mono or dual antiplatelet regimen prior to and after the procedures (depend on concomitant or prior stenting). The most common complication is thromboembolism. Delayed ipsilateral parenchymal hemorrhage, a very serious but rare complication, was also reported.
+Endosaccular flow disruption devices, also simply known as flow disruptors, are used for the treatment of saccular, wide-neck, and usually bifurcation <a title="Intracranial aneurysms" href="/articles/saccular-cerebral-aneurysm">intracranial aneurysms</a>. Their primary function is to stop blood from flowing into the aneurysm, allowing time for the aneurysm to heal. They are usually tightly packed nitinol-based material in different shapes. Currently (as of 2020) there are four types of flow disruptors:<ul>
+<li>Woven EndoBridge (WEB) Aneurysm Embolization System</li>
+<li>LUNA™ Aneurysm Embolization System</li>
+<li>Medina Embolic Device (MED)</li>
+<li>Contour Neurovascular System™</li>
+</ul>Antiplatelet regimen differs between institutions ranging from mono or dual antiplatelet regimen prior to and after the procedures (depend on concomitant or prior stenting). <h4>Complications</h4>The most common complication is thromboembolism. Delayed ipsilateral parenchymal hemorrhage, a very serious but rare complication, was also reported. <h4>Outcomes</h4>Among them, WEB is the most widely known and studied device. Large European multicenter trials (WEBCAST and WEBCAST 2) illustrated a very high success rate (complete occlusion or neck remnant at one-year follow-up) in 80% with no device-related mortality and only 1.8-2% morbidity.

References changed:

1. Gawlitza M, Soize S, Januel A et al. Treatment of Recurrent Aneurysms Using the Woven EndoBridge (WEB): Anatomical and Clinical Results. J Neurointerv Surg. 2018;10(7):629-33. <a href="https://doi.org/10.1136/neurintsurg-2017-013287">doi:10.1136/neurintsurg-2017-013287</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/29054913">Pubmed</a>
2. Pierot L, Gubucz I, Buhk J et al. Safety and Efficacy of Aneurysm Treatment with the WEB: Results of the WEBCAST 2 Study. AJNR Am J Neuroradiol. 2017;38(6):1151-5. <a href="https://doi.org/10.3174/ajnr.A5178">doi:10.3174/ajnr.A5178</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28450432">Pubmed</a>
3. Dmytriw A, Salem M, Yang V et al. Endosaccular Flow Disruption: A New Frontier in Endovascular Aneurysm Management. Neurosurgery. 2020;86(2):170-81. <a href="https://doi.org/10.1093/neuros/nyz017">doi:10.1093/neuros/nyz017</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/30834934">Pubmed</a>
4. Pierot L, Costalat V, Moret J et al. Safety and Efficacy of Aneurysm Treatment with WEB: Results of the WEBCAST Study. J Neurosurg. 2016;124(5):1250-6. <a href="https://doi.org/10.3171/2015.2.JNS142634">doi:10.3171/2015.2.JNS142634</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/26381253">Pubmed</a>
L. Pierot, I. Gubucz, J.H. Buhk, M. Holtmannspötter, D. Herbreteau, L. Stockx, L. Spelle, J. Berkefeld, A.-C. Januel, A. Molyneux, J.V. Byrne, J. Fiehler, I. Szikora, X. Barreau. Safety and Efficacy of Aneurysm Treatment with the WEB: Results of the WEBCAST 2 Study. (2017) American Journal of Neuroradiology. 38 (6): 1151. <a href="https://doi.org/10.3174/ajnr.A5178">doi:10.3174/ajnr.A5178</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28450432">Pubmed</a>
Gawlitza M, Soize S, Januel AC, Mihalea C, Metaxas GE, Cognard C, Pierot L. Treatment of recurrent aneurysms using the Woven EndoBridge (WEB): anatomical and clinical results. (2018) Journal of neurointerventional surgery. 10 (7): 629-633. <a href="https://doi.org/10.1136/neurintsurg-2017-013287">doi:10.1136/neurintsurg-2017-013287</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/29054913">Pubmed</a>
Gawlitza M, Soize S, Januel AC, Mihalea C, Metaxas GE, Cognard C, Pierot L. Treatment of recurrent aneurysms using the Woven EndoBridge (WEB): anatomical and clinical results. (2018) Journal of neurointerventional surgery. 10 (7): 629-633. <a href="https://doi.org/10.1136/neurintsurg-2017-013287">doi:10.1136/neurintsurg-2017-013287</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/29054913">Pubmed</a>
L. Pierot, I. Gubucz, J.H. Buhk, M. Holtmannspötter, D. Herbreteau, L. Stockx, L. Spelle, J. Berkefeld, A.-C. Januel, A. Molyneux, J.V. Byrne, J. Fiehler, I. Szikora, X. Barreau. Safety and Efficacy of Aneurysm Treatment with the WEB: Results of the WEBCAST 2 Study. (2017) American Journal of Neuroradiology. 38 (6): 1151. <a href="https://doi.org/10.3174/ajnr.A5178">doi:10.3174/ajnr.A5178</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28450432">Pubmed</a>
Dmytriw, Adam A, Salem, Mohamed M, Yang, Victor X D, Krings, Timo, Pereira, Vitor M, Moore, Justin M, Thomas, Ajith J. Endosaccular Flow Disruption: A New Frontier in Endovascular Aneurysm Management. (2020) Neurosurgery. 86 (2): 170. <a href="https://doi.org/10.1093/neuros/nyz017">doi:10.1093/neuros/nyz017</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/30834934">Pubmed</a>
Laurent Pierot, Vincent Costalat, Jacques Moret, Istvan Szikora, Joachim Klisch, Denis Herbreteau, Markus Holtmannspötter, Werner Weber, Anne-Christine Januel, Thomas Liebig, Vojtech Sychra, Christoph Strasilla, Christophe Cognard, Alain Bonafé, Andrew Molyneux, James V. Byrne, Laurent Spelle. Safety and efficacy of aneurysm treatment with WEB: results of the WEBCAST study. (2016) Journal of Neurosurgery. 124 (5): 1250. <a href="https://doi.org/10.3171/2015.2.JNS142634">doi:10.3171/2015.2.JNS142634</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/26381253">Pubmed</a>